摘要
中国积极推进消灭脊髓灰质炎(脊灰)终结战略计划,分阶段将灭活脊灰病毒疫苗(Inactivated Poliovirus Vaccine,IPV)纳入免疫规划,预期2016年4月与全球同步停服三价(Trivalent)口服脊灰减毒活疫苗(Oral Poliomyelitis Attenuated Live Vaccine,t OPV),开始接种二价(Bivalent)OPV(b OPV)。为澄清对一些技术问题的认识,世界卫生组织驻中国代表处会同国内外相关专家,讨论了中国部分专业人员提出的主要技术和政策问题,包括停用OPV的原因,b OPV替代t OPV使用的步骤,转换前减少风险的准备等,形成专家解读,供相关部门和专业人员在推进消灭脊灰终结战略计划中参考。
China is actively implementing the Poliomyelitis Eradication Endgame Strategic Plan,with inactivated poliovirus vaccine（ IPV） introduction into the Expanded Program on Immunization（ EPI） in a phased manner. Switching from trivalent oral poliomyelitis attenuated live vaccine（ t OPV） to bivalent OPV（ b OPV） in China is anticipated to happen in a globally synchronized switch in April 2016. To clarify questions and address concerns from experts in different institutions,the World Health Organization（ WHO） China Office,together with international and national experts,discussed keytechnical and policy issues in depth. These included reasons for stopping OPV,steps in the switch from t OPV to b OPV,and preparations to mitigate risk. These questions and concerns were addressed with international experts＇ interpretationsthat can be used as reference for relevant departments and staff working onthe Polio Eradication Endgame Strategic Plan in China.
出处
《中国疫苗和免疫》
北大核心
2015年第4期439-443,共5页
Chinese Journal of Vaccines and Immunization
